These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 10510111)

  • 41. Chronic inflammation is negatively associated with prostate cancer and high-grade prostatic intraepithelial neoplasia on needle biopsy.
    Karakiewicz PI; Benayoun S; Bégin LR; Duclos A; Valiquette L; McCormack M; Bénard F; Saad F; Perrotte P
    Int J Clin Pract; 2007 Mar; 61(3):425-30. PubMed ID: 17313610
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.
    Magklara A; Scorilas A; Catalona WJ; Diamandis EP
    Clin Chem; 1999 Nov; 45(11):1960-6. PubMed ID: 10545066
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Analysis of repeated biopsy results within 1 year after a noncancer diagnosis.
    O'dowd GJ; Miller MC; Orozco R; Veltri RW
    Urology; 2000 Apr; 55(4):553-9. PubMed ID: 10736500
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases.
    Carlson GD; Calvanese CB; Partin AW
    Urology; 1998 Sep; 52(3):455-61. PubMed ID: 9730460
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
    Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
    J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions.
    Goel T; Garg S
    Urol Int; 2009; 82(3):286-90. PubMed ID: 19440015
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA.
    Van Cangh PJ; De Nayer P; De Vischer L; Sauvage P; Tombal B; Lorge F; Wese FX; Opsomer R
    Urology; 1996 Dec; 48(6A Suppl):67-70. PubMed ID: 8973703
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is repeat prostate biopsy for high-grade prostatic intraepithelial neoplasia necessary after routine 12-core sampling?
    Lefkowitz GK; Sidhu GS; Torre P; Lepor H; Taneja SS
    Urology; 2001 Dec; 58(6):999-1003. PubMed ID: 11744476
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
    Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
    Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Basal cell hyperplasia (BCH) versus high grade prostatic intraepithelial neoplasia (HGPIN) in tiny prostatic needle biopsies: Unusual diagnostic dilemma.
    Yassin Fel-Z; Muhammad EM; Zaki M; Saleem MD; Mohammed RA
    J Egypt Natl Canc Inst; 2014 Mar; 26(1):15-22. PubMed ID: 24565678
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum free prostate-specific antigen in the diagnosis of prostate cancer.
    Leung HY; Lai LC; Day J; Thomson J; Neal DE; Hamdy FC
    Br J Urol; 1997 Aug; 80(2):256-9. PubMed ID: 9284198
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
    Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
    Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen.
    Steuber T; Nurmikko P; Haese A; Pettersson K; Graefen M; Hammerer P; Huland H; Lilja H
    J Urol; 2002 Nov; 168(5):1917-22. PubMed ID: 12394676
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
    Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
    Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of high-grade prostatic intraepithelial neoplasia for biochemical relapse of prostate carcinoma after radical prostatectomy.
    Auskalnis S; Milonas D; Jievaltas M; Vaiciūnas K; Mickevicius A; Gudinaviciene I
    Medicina (Kaunas); 2010; 46(9):604-10. PubMed ID: 21252594
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The incidence of lesions associated with prostatic biopsy and its effect on the serum concentration of the prostate-specific antigen].
    Morote Robles J; López López M; Encabo Duro G; de Torres Ramírez I
    Actas Urol Esp; 1999 May; 23(5):400-5. PubMed ID: 10427813
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia.
    Marley GM; Miller MC; Kattan MW; Zhao G; Patton KP; Vessella RL; Wright GL; Schellhammer PF; Veltri RW
    Urology; 1996 Dec; 48(6A Suppl):16-22. PubMed ID: 8973695
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vascular endothelial growth factor (VEGF) and prostate pathology.
    Botelho F; Pina F; Silva P; Figueiredo G; Cruz F; Lunet N
    Int Braz J Urol; 2010; 36(4):430-7; discussion 438. PubMed ID: 20815949
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0 ng/mL.
    Okegawa T; Kinjo M; Watanabe K; Noda H; Kato M; Miyata A; Murata A; Yoshii M; Nutahara K; Higashihara E
    BJU Int; 2000 Apr; 85(6):708-14. PubMed ID: 10759671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.